Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) were down 7.5% during trading on Tuesday following insider selling activity. The stock traded as low as $3.67 and last traded at $3.97. Approximately 6,731,720 shares changed hands during trading, an increase of 539% from the average daily volume of 1,053,620 shares. The stock had previously closed at $4.29.

Specifically, insider Pamela P. Palmer bought 37,000 shares of AcelRx Pharmaceuticals stock in a transaction dated Monday, August 6th. The shares were acquired at an average cost of $2.75 per share, with a total value of $101,750.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Lawrence G. Hamel sold 6,953 shares of the business’s stock in a transaction on Monday, September 24th. The stock was sold at an average price of $4.50, for a total transaction of $31,288.50. Following the transaction, the insider now directly owns 24,371 shares in the company, valued at $109,669.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 57,300 shares of company stock worth $159,552. 25.50% of the stock is currently owned by corporate insiders.

A number of research analysts have recently commented on ACRX shares. Zacks Investment Research cut shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Oppenheimer reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, August 3rd. Jefferies Financial Group raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Monday. Cantor Fitzgerald set a $6.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 1st. Finally, LADENBURG THALM/SH SH started coverage on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 16th. They set a “buy” rating and a $7.00 target price on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. AcelRx Pharmaceuticals has an average rating of “Buy” and an average price target of $7.50.

The company has a current ratio of 4.01, a quick ratio of 3.96 and a debt-to-equity ratio of -0.15. The stock has a market capitalization of $233.31 million, a P/E ratio of -3.61 and a beta of 2.04.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $0.93 million. Research analysts anticipate that AcelRx Pharmaceuticals Inc will post -0.83 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Lincoln Capital Corp raised its holdings in AcelRx Pharmaceuticals by 83.3% in the third quarter. Lincoln Capital Corp now owns 62,775 shares of the specialty pharmaceutical company’s stock valued at $242,000 after acquiring an additional 28,525 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in AcelRx Pharmaceuticals in the second quarter valued at $1,676,000. FMR LLC raised its holdings in AcelRx Pharmaceuticals by 1,094.6% in the second quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after acquiring an additional 273,644 shares in the last quarter. BlackRock Inc. raised its holdings in AcelRx Pharmaceuticals by 2.7% in the second quarter. BlackRock Inc. now owns 673,115 shares of the specialty pharmaceutical company’s stock valued at $2,271,000 after acquiring an additional 17,737 shares in the last quarter. Finally, Granite Investment Partners LLC acquired a new stake in AcelRx Pharmaceuticals in the second quarter valued at $182,000. 8.57% of the stock is currently owned by hedge funds and other institutional investors.

AcelRx Pharmaceuticals Company Profile (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Read More: S&P 500 Index

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.